IRIS Capital Backs SYNBIOTIC's Expansion Plans

SYNBIOTIC SE, a leader in the European medical cannabis and industrial hemp sector, has entered a strategic partnership with IRIS Capital Investment. The French venture capital firm has committed to invest up to EUR 2.4 million in SYNBIOTIC through non-interest-bearing convertible bonds, enhancing the group's growth strategy. The first issuance of these bonds is set for late April 2025.

Fabrice Evangelista, Managing Director of IRIS Capital, emphasized the alliance's importance beyond financial aid, highlighting its strategic value. SYNBIOTIC's CEO, Daniel Kruse, expressed pride in IRIS's support of their growth plans.

Meanwhile, SYNBIOTIC continues to strengthen its industry presence. At the upcoming Talman event in Berlin, they will showcase a strategic partnership with GOC NEXUS. Additionally, WEECO Pharma, SYNBIOTIC's wholesale unit, exceeded its sales targets, prompting revised, optimistic forecasts for the coming years.